Hematology Today—May 11, 2026

This week’s Hematology update highlights clinical financing activity, precision diagnostics advances, reimbursement progress, early-stage hematology studies, and expanding cell therapy access initiatives.

Dive deeper

💊 CellCentric funds pivotal inobrodib trials [1] [UK/US • 06 May 2026]

https://www.cellcentric.com/press-release/cellcentric-announces-oversubscribed-220-million-series-d-financing-to-advance-pivotal-trials-of-inobrodib-in-multiple-myeloma/
Context: CellCentric (Cambridge, UK and Boston) is developing inobrodib, a first-in-class oral p300/CBP inhibitor for multiple myeloma.
Key point: The company closed an oversubscribed $220 million Series D to support DOMMINO-1 and a planned global Phase 3 DOMMINO-2 start in 2H 2026.
Implication: Signals pipeline investment and modality expansion.

🧬 TGen launches JAYseq myeloma WGS test [2] [US • 07 May 2026]

https://www.tgen.org/news/new-tgen-clinical-test-for-multiple-myeloma-consolidates-multiple-analyses-and-provides-detailed-information-in-3-days/
Context: JAYseq is a whole-genome sequencing assay from TGen Clinical Laboratory, part of TGen and City of Hope.
Key point: The test is intended for newly diagnosed, relapsed or refractory multiple myeloma, or related plasma cell disorders, with results returned in 72 hours.
Implication: May expand screening, initiation, and follow-up at scale.

🧫 LTZ raises $38 million for myeloid engager pipeline [3] [US/China • 06 May 2026]

https://www.businesswire.com/news/home/20260428631901/en/LTZ-Therapeutics-Raises-%2438-Million-in-Support-of-Advancing-Myeloid-Engager-Immunotherapy-Pipeline
Context: LTZ Therapeutics operates in Redwood City and Shenzhen and is developing Universal Myeloid Cell Engager (U-MCE) immunotherapies.
Key point: LTZ raised $38 million to support Phase 1 LTZ-301 enrollment and the IND filing and Phase 1 initiation of LTZ-232.
Implication: Signals pipeline investment and modality expansion.

☢️ Cellectar reports 12-month CLOVER WaM data [4] [US • 05 May 2026]

https://www.cellectar.com/investors/news-events/press-releases/detail/390/cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of-iopofosine-i-131-in-rr-waldenstrm-macroglobulinemia
Context: CLOVER WaM evaluated iopofosine I 131 in relapsed or refractory Waldenström macroglobulinemia, with minimum 12-month follow-up for all enrolled patients.
Key point: Cellectar reported 83.6% ORR, 61.8% MRR, 17.8-month median duration of response, and 13.5-month median PFS in the per-protocol population.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Electra doses first Phase 1 T cell malignancy patient [5] [US • 05 May 2026]

https://electra-therapeutics.com/electra-therapeutics-to-announce-first-patient-dosed-in-phase-1/
Context: Ipsoprubart (ELA026) is a first-in-class SIRP-targeting monoclonal antibody from Electra Therapeutics.
Key point: Electra dosed the first patient in an open-label Phase 1 study of ipsoprubart monotherapy in relapsed or refractory T cell malignancies.
Implication: May influence prescriber choice and payer reviews pending full data.

🔬 BioOra secures global Atla-cel rights expansion [6] [New Zealand • 06 May 2026]

https://bioora.com/our-stories/bioora-limited-and-wellington-zhaotai-therapies-limited-wztl-sign-heads-of-terms-to-advance-their-global-expansion-of-car-t-cell-therapy
Context: BioOra and Wellington Zhaotai are advancing Atla-cel, an autologous third-generation anti-CD19 CAR T-cell therapy.
Key point: BioOra signed binding Heads of Terms for exclusive rights outside China and India, including the US, Europe and UK.
Implication: Signals pipeline investment and modality expansion.

🩸 Vertex secures CASGEVY reimbursement in Germany [7] [Germany • 06 May 2026]

https://news.vrtx.com/news-releases/news-release-details/vertex-announces-casgevyr-reimbursement-agreement-treatment-1
Context: CASGEVY (exagamglogene autotemcel) is a CRISPR/Cas9 gene-edited therapy for eligible SCD and TDT patients aged 12 years and older.
Key point: Vertex signed a reimbursement agreement with GKV-Spitzenverband to support access in Germany.
Implication: May expand screening, initiation, and follow-up at scale.

Why it matters

Late-stage hematology assets drew capital, with CellCentric and Cellectar linking financing or data maturity to registration pathways.
Precision diagnostics and cell therapy access remain active themes, shown by TGen’s JAYseq launch and Vertex’s German CASGEVY reimbursement.
Myeloid biology and SIRP targeting continue to move into early clinical oncology studies.
CAR T commercialization is expanding beyond initial regional markets, with BioOra seeking broader access for Atla-cel.
Multiple stories focus on access, scalability, or administration burden, including oral inobrodib, 72-hour WGS, automated CAR T manufacturing, and one-time gene editing.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Hematology archive on our research hub page.

FAQ

What is CellCentric using the $220 million Series D for?

CellCentric said proceeds will support inobrodib studies in multiple myeloma, including DOMMINO-1 and the planned Phase 3 DOMMINO-2 trial. The company also cited expansion into combination and maintenance settings. [1]

What does TGen’s JAYseq test do for multiple myeloma?

JAYseq provides a 72-hour whole-genome sequencing profile for multiple myeloma and related plasma cell disorders. TGen said it can detect mutations, insertions, deletions, copy number changes, translocations, and complex rearrangements. [2]

What is LTZ-301?

LTZ-301 is LTZ Therapeutics’ lead myeloid engager bispecific antibody targeting CD79b+ B-cells. It is in an ongoing Phase 1 study in relapsed or refractory non-Hodgkin lymphoma. [3]

What did Cellectar report from CLOVER WaM?

Cellectar reported updated 12-month follow-up data for iopofosine I 131 in relapsed or refractory Waldenström macroglobulinemia. The company reported ORR, MRR, duration of response, and PFS data in the per-protocol population. [4]

What is Electra studying with ipsoprubart?

Electra is evaluating ipsoprubart monotherapy in adults with relapsed or refractory T cell malignancies in an open-label Phase 1 study. The primary endpoint is safety. [5]

What changed for CASGEVY in Germany?

Vertex signed a reimbursement agreement with GKV-Spitzenverband for CASGEVY in eligible patients aged 12 years and older with severe sickle cell disease or transfusion-dependent beta thalassemia. [7]

Entities / Keywords

CellCentric, inobrodib, p300/CBP inhibitor, DOMMINO-1, DOMMINO-2, InoPd, multiple myeloma, RRMM
TGen, City of Hope, JAYseq, ALTseq, whole-genome sequencing, WGS, CD138+ cells, multiple myeloma
LTZ Therapeutics, U-MCE, LTZ-301, LTZ-232, myeloid engager, CD79b, r/r NHL, autoimmune disease
Cellectar Biosciences, iopofosine I 131, CLOVER WaM, Waldenström macroglobulinemia, BTKi, PDC
Electra Therapeutics, ipsoprubart, ELA026, SIRP, T cell malignancies, sHLH
BioOra, Wellington Zhaotai, Atla-cel, WZTL-002, anti-CD19 CAR T, ENABLE-1, ENABLE-2, Cocoon platform
Vertex, CASGEVY, exagamglogene autotemcel, CRISPR/Cas9, sickle cell disease, SCD, transfusion-dependent beta thalassemia, TDT, GKV-Spitzenverband